Evaluation of efficacy of Letrozole on the duration and severity of Ovarian hyperstimulation syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141008019464N2

Enrollment

Registered

2020-12-21

Start date

2019-09-22

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian hyperstimulation syndrome. Hyperstimulation of ovaries

Interventions

Intervention 1: Intervention group: Prescription of Letrozole tablet 2.5 mg from Abu Reihan company with chemical formula C17H11N5 1 orally daily for 10 days along with routine treatment of ovarian h

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Having Ovarian hyperstimulation syndrome

Exclusion criteria

Exclusion criteria: Lack of incidence of hyperstimulation syndrome after receiving ovarian stimulant drug due to infertility Patient dissatisfaction to participate in the study

Design outcomes

Primary

Measure	Time frame
Duration of Ovarian hyperstimulation syndrome. Timepoint: 2-3 weeks after intervention. Method of measurement: laboratory tests.	—

Secondary

Measure	Time frame
Liver enzymes. Timepoint: 2 weeks after intervention. Method of measurement: laboratory tests.;Hematocrit. Timepoint: 2 weeks after intervention. Method of measurement: laboratory tests.;Ratio of urea to creatinine. Timepoint: 2 weeks after intervention. Method of measurement: laboratory tests.;Evacuation of ascites. Timepoint: 7 & 14 days after intervention. Method of measurement: Number of ascites Evacuations.;Existence of thrombosis. Timepoint: 7 & 14 days after intervention. Method of measurement: Ultrasound.;Ovary size. Timepoint: 2 weeks after intervention. Method of measurement: Ultrasound.;Shortness of breath. Timepoint: 7 & 14 days after intervention. Method of measurement: history.	—

Measure

Time frame

Liver enzymes. Timepoint: 2 weeks after intervention. Method of measurement: laboratory tests.;Hematocrit. Timepoint: 2 weeks after intervention. Method of measurement: laboratory tests.;Ratio of urea to creatinine. Timepoint: 2 weeks after intervention. Method of measurement: laboratory tests.;Evacuation of ascites. Timepoint: 7 & 14 days after intervention. Method of measurement: Number of ascites Evacuations.;Existence of thrombosis. Timepoint: 7 & 14 days after intervention. Method of measurement: Ultrasound.;Ovary size. Timepoint: 2 weeks after intervention. Method of measurement: Ultrasound.;Shortness of breath. Timepoint: 7 & 14 days after intervention. Method of measurement: history.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVictoria Habibzadeh

Kerman University of Medical Sciences

v_habibzadeh@kmu.ac.ir+98 34 3223 5011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026